Sponsored Links 
Top Health Equity Funds
Print
ShareToday we are featuring top-performing “Health" equity mutual funds , which primarily invest in equity securities of healthcare and related companies.
Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds.
3 Healthy Picks
Eaton Vance Worldwide Health Sciences A (ETHSX) long-term capital growth by investing in a global and diversified portfolio of health sciences companies. It was incepted in July 1985.
The fund pursues its objective by investing in worldwide health sciences portfolio. The fund invests primarily in common stocks of companies engaged in the development, production or distribution of products related to scientific advances in health care and companies with a broad range of market capitalization's, including small companies.
The fund has an expense ratio of 2.06% and a portfolio turnover of 48% as May 2009. The fund offers dividends and capital gains annually.
Samuel D. Isaly has been lead manager of the fund since 26-Jul-85. Before joining OrbiMed Advisors Isaly was president and partner with Mehta and Isaly Asset Management.
Evergreen Health Care Fund A (EHABX) seeks long-term capital growth. The fund was incepted in December 1999.
The fund invests primarily in equity securities of healthcare companies. The fund is suitable for those investors who seek long-term growth of capital and a fund with the potential for higher return while being able to tolerate substantial volatility over time.
The fund offers dividends and capital gains, if any, annually. It has an expense ratio of 1.84%.
Robert C. Junkin has been lead manager of the fund since March2007. Before joining Evergreen in 2007, Junkin served as a vice president and portfolio manager with MFC Global Investment Management.
Rydex Biotechnology Inv (RYOIX) was incepted in April 1998. The fund seeks capital appreciation by investing in companies that are involved in the biotechnology industry, including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.
The fund invests substantially all of its assets in equity securities of biotechnology companies that are traded in the United States. The fund may also engage in futures and options transactions, purchase ADRs and U.S. government securities, and enter into repurchase agreements.
Shareholders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy”) fund. As of June 2009, it has a portfolio turnover of 370%.
Michael P. Byrum has been Lead Manager of the fund since 01-Apr-98. Byrum is a Charted Financial Analyst and is president and CIO of Rydex Investments.
Discover Many More Funds
Learn more about the new Zacks Mutual Fund Rank and discover some of the best market-beating mutual funds by browsing our new mutual funds section. This part of Zacks.com offers a variety of tools, including mutual fund research, a new mutual fund screener, helpful answers to frequently asked questions and quick access to prospectuses and other information.
By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward.
Read the full analyst report on ETHSX
Read the full analyst report on EHABX
Read the full analyst report on RYOIX
Loading Stories...
|
||||||||||||||
More Zacks Resources
More Zacks Links
| Market Summary | May 26, 2012 05:04 am ET |
-74.92